Health & Biotech
At Paradigm, we firmly believe that the key to addressing unmet medical needs lies in unlocking the potential of forgotten compounds. Our strategy is to take unconventional routes to develop safe and effective treatments for clinical conditions that lack viable options.
Our current primary focus is the development of injectable pentosan polysulfate sodium (iPPS/Zilosul®), for the treatment of osteoarthritis (OA). An ability to provide a safe an effective treatment for OA is a blockbuster market opportunity as there are limited therapeutic solutions available. We’ve charged ahead into global phase 3 trials, addressing the core components of the disease: inflammation, pain, and regeneration. Zilosul® possesses the remarkable potential to provide long-term pain reduction and modify the underlying course of this debilitating disease.
With our headquarters in Melbourne, Australia, and strategic offices in the European Union and the United States, Paradigm is poised to make a global impact. Our international presence reflects our commitment to delivering ground breaking treatments to patients worldwide.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
Health Check: Sonic Healthcare is cashed up and ready to boom as earnings improve
Health & Biotech
Health Check: Which biotech boards are at risk of a ‘second strike’?
Health & Biotech
ASX Quarterly Health Wrap: Action for Dimerix Phase 3 kidney trial
News
Closing Bell: ASX dips as AGL stalls; Talga skyrockets after Sweden approves graphite mine
News
Market Highlights: Gold hits new highs while Meta misses the mark; and 5 ASX small caps to watch
Health & Biotech
Biocurious: Cracking the code on Paradigm’s valuation enigma
Health & Biotech
Health Check: Just the news we ‘kneed’ as Paradigm aims to kick-start US osteo trial
Health & Biotech
ASX innovators reshaping traditional medical treatments
Health & Biotech
ASX stocks leading clinical trials in Australia
Stockhead TV
Break it Down: Paradigm Biopharmaceuticals en route to Phase 3 clinical trial with FDA support
News
Closing Bell: ASX choppy as traders sit it out; BPM soars on Mt Gibson gold find
Health & Biotech
Paradigm steps closer to Phase 3 trial for knee arthritis treatment after FDA feedback
Health & Biotech
Health Check: Paradigm receives FDA guidance on proposed trial for dodgy knees
News
Market Highlights: Cryptos make their move ahead of Fed; and 5 ASX small caps to watch today
Health & Biotech
Bio Curious: How Dimerix negotiates the ‘valleys of death’ on the winding road to drug approval
Investor Guides
Investor Guide: Health & Biotech FY2025 featuring Tim Boreham
Health & Biotech